Integrin Antagonists 27

Cat. No.: HY-18668

CAS No.: 593274-97-6

Molecular Formula: $C_{24}H_{20}N_4O_5$

Molecular Weight: 444.44

Target: Integrin

Pathway: Cytoskeleton

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (225.00 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.2500 mL	11.2501 mL	22.5002 mL
5 mM	0.4500 mL	2.2500 mL	4.5000 mL
10 mM	0.2250 mL	1.1250 mL	2.2500 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.63 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (5.63 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent. Target: Integrinin vitro: Integrin Antagonists 27 is treated with a panel of cancer cell-lines (breast cancer cell line MDA-MB-435, breast cancer cell lines MCF-7, mouse fibroblast NIH3T3, ovarian cancer cell line HEY, lung cancer cell line NCI-H1975) with all IC50 of >20 uM.

REFERENCES

[1]. Dayam R, et al. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents. J Med Chem. 2006 Jul 27;49(15):4526-4534.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA